Therapies administered before rituximab treatment
| Patient no. . | First-line treatment . | Second-line treatment . | Interval from first- to second-line treatment, mo . | Third-line treatment . | Interval from second- to third-line treatment, mo . | Splenectomy . | Interval from diagnosis to splenectomy . |
|---|---|---|---|---|---|---|---|
| Responders | |||||||
| 1 | IV MPDN | Oral PDN | 0.5 | IV IgG | 0.5 | — | — |
| 2 | IV IgG | Oral PDN | 1.9 | — | — | — | — |
| 3 | IV IgG | Oral PDN | 0.3 | IV MPDN | 0.4 | ||
| 4 | Oral PDN + AZA | IV IgG | 18.0 | CY | 3.8 | Yes | 22 |
| 5 | Oral PDN | Cs-A | 0.3 | — | — | — | — |
| 6 | IV IgG | Oral PDN | 0.3 | IV MPDN | 7.6 | — | — |
| 7 | Oral PDN | IV IgG | 6.1 | Oral PDN | 5.2 | — | — |
| 8 | Oral PDN | IV IgG | 0.3 | Cs-A + AZA | 4.5 | — | — |
| 9 | IV MPDN | IV MPDN | 3.9 | IV IgG | 0.5 | — | — |
| 10 | IV MPDN | AZA | 0.3 | — | — | — | — |
| Responders who relapsed | |||||||
| 11 | IV MPDN | AZA | 0.3 | Cs-A + AZA | 1 | — | — |
| 12 | Oral PDN | IV IgG | 0.4 | AZA | 23 | — | — |
| 13 | IV IgG | IV MPDN | 15.4 | Cs-A + AZA | 30 | — | — |
| Nonresponders | |||||||
| 14 | IV MPDN | AZA | 0.8 | — | — | — | — |
| 15 | IV MPDN | IV IgG | 3.1 | Cs-A + AZA | 8 | Yes | 16 |
| Median | 0.5 | 4.5 | |||||
| Range | 0.3-18 | 0.4-30 |
| Patient no. . | First-line treatment . | Second-line treatment . | Interval from first- to second-line treatment, mo . | Third-line treatment . | Interval from second- to third-line treatment, mo . | Splenectomy . | Interval from diagnosis to splenectomy . |
|---|---|---|---|---|---|---|---|
| Responders | |||||||
| 1 | IV MPDN | Oral PDN | 0.5 | IV IgG | 0.5 | — | — |
| 2 | IV IgG | Oral PDN | 1.9 | — | — | — | — |
| 3 | IV IgG | Oral PDN | 0.3 | IV MPDN | 0.4 | ||
| 4 | Oral PDN + AZA | IV IgG | 18.0 | CY | 3.8 | Yes | 22 |
| 5 | Oral PDN | Cs-A | 0.3 | — | — | — | — |
| 6 | IV IgG | Oral PDN | 0.3 | IV MPDN | 7.6 | — | — |
| 7 | Oral PDN | IV IgG | 6.1 | Oral PDN | 5.2 | — | — |
| 8 | Oral PDN | IV IgG | 0.3 | Cs-A + AZA | 4.5 | — | — |
| 9 | IV MPDN | IV MPDN | 3.9 | IV IgG | 0.5 | — | — |
| 10 | IV MPDN | AZA | 0.3 | — | — | — | — |
| Responders who relapsed | |||||||
| 11 | IV MPDN | AZA | 0.3 | Cs-A + AZA | 1 | — | — |
| 12 | Oral PDN | IV IgG | 0.4 | AZA | 23 | — | — |
| 13 | IV IgG | IV MPDN | 15.4 | Cs-A + AZA | 30 | — | — |
| Nonresponders | |||||||
| 14 | IV MPDN | AZA | 0.8 | — | — | — | — |
| 15 | IV MPDN | IV IgG | 3.1 | Cs-A + AZA | 8 | Yes | 16 |
| Median | 0.5 | 4.5 | |||||
| Range | 0.3-18 | 0.4-30 |
IV MPDN indicates intravenous methylprednisolone; oral PDN, oral prednisone; IV IgG, intravenous immunoglobulin; AZA, azathioprine; Cs-A, cyclosporine A; CY, cyclophosphamide; —, not applicable.